Ameet Sarpatwari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/20911/publications.pdf

Version: 2024-02-01

97 papers	2,220 citations	331538 21 h-index	243529 44 g-index
98 all docs	98 docs citations	98 times ranked	2395 citing authors

#	Article	IF	Citations
1	Civil commitment for opioid misuse: do short-term benefits outweigh long-term harms?. Journal of Medical Ethics, 2022, 48, 608-610.	1.0	3
2	Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings. British Journal of Clinical Pharmacology, 2022, 88, 713-722.	1.1	8
3	COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach?. Annals of Internal Medicine, 2022, 175, 280-282.	2.0	1
4	COVID-19 antivirals must not affect HIV drug supply. Lancet HIV,the, 2022, 9, e7-e9.	2.1	2
5	Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling. Journal of Clinical Oncology, 2022, 40, 1102-1110.	0.8	3
6	State Restrictions on Mifepristone Access â€" The Case for Federal Preemption. New England Journal of Medicine, 2022, , .	13.9	7
7	Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. BMJ Quality and Safety, 2022, 31, 179-190.	1.8	6
8	The characteristics of patents impacting availability of biosimilars. Nature Biotechnology, 2022, 40, 22-25.	9.4	9
9	Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use. JAMA Network Open, 2022, 5, e2144386.	2.8	7
10	Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability. JAMA - Journal of the American Medical Association, 2022, , .	3.8	4
11	Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. Drug Safety, 2022, , 1.	1.4	2
12	State Laws and Generic Substitution in the Year After New Generic Competition. Value in Health, 2022, , .	0.1	1
13	Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved Drugs. Health Affairs, 2022, 41, 713-721.	2.5	7
14	Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. Clinical Pharmacology and Therapeutics, 2021, 109, 1424-1442.	2.3	12
15	Ensuring Safe Access to Mifepristone During the Pandemic and Beyond. Annals of Internal Medicine, 2021, 174, 105-106.	2.0	7
16	Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. Drug Safety, 2021, 44, 327-335.	1.4	4
17	Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions. JAMA Internal Medicine, 2021, 181, 16.	2.6	22
18	Corrections to Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions. JAMA Internal Medicine, 2021, 181, 144.	2.6	1

#	Article	IF	Citations
19	Frequency of First Generic Drug Approvals With â€œSkinny Labelsâ€•in the United States. JAMA Internal Medicine, 2021, 181, 995-997.	2.6	8
20	Identifying potential prescription drug product hopping. Nature Biotechnology, 2021, 39, 414-417.	9.4	2
21	A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. Drug Safety, 2021, 44, 743-751.	1.4	7
22	Substitution of Generic Drugs and Biosimilarsâ€”Reply. JAMA Internal Medicine, 2021, 181, 568.	2.6	0
23	Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear. Health Affairs, 2021, 40, 772-778.	2.5	5
24	Cost to Medicare of Delayed Adalimumab Biosimilar Availability. Clinical Pharmacology and Therapeutics, 2021, 110, 1050-1056.	2.3	11
25	Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation. Health Affairs, 2021, 40, 1198-1205.	2.5	15
26	The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. Mayo Clinic Proceedings, 2021, 96, 2305-2308.	1.4	0
27	Preventing medical-deviceâ€“borne outbreaks: High-level disinfection policy for duodenoscopes. Infection Control and Hospital Epidemiology, 2021, 42, 334-337.	1.0	1
28	Promoting Biosimilar Competition by Revising Medicare Reimbursement Rules. JAMA Network Open, 2021, 4, e2134463.	2.8	3
29	FDA and EMA Biosimilar Approvals. Journal of General Internal Medicine, 2020, 35, 1908-1910.	1.3	11
30	Novelty of Active Ingredients in High-Cost Brand-Name Drugs. Journal of General Internal Medicine, 2020, 35, 2219-2221.	1.3	1
31	Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States. JAMA - Journal of the American Medical Association, 2020, 323, 87.	3.8	9
32	Clinical Development Times for Biosimilars in the United States. Mayo Clinic Proceedings, 2020, 95, 2152-2154.	1.4	3
33	Revisiting the National Institutes of Health Fair Pricing Condition: Promoting the Affordability of Drugs Developed With Government Support. Annals of Internal Medicine, 2020, 172, 348-350.	2.0	9
34	Missed Opportunities on Emergency Remdesivir Use. JAMA - Journal of the American Medical Association, 2020, 324, 331.	3.8	15
35	Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?. BMJ, The, 2020, 371, m3841.	3.0	7
36	A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways. Nature Biotechnology, 2020, 38, 1253-1256.	9.4	8

#	Article	IF	Citations
37	Development of a National Public Pharmaceutical Research and Development Institute. Journal of Law, Medicine and Ethics, 2020, 48, 225-227.	0.4	0
38	Communicating emerging risks of SGLT2 inhibitorsâ€"timeliness and transparency of medicine regulators. BMJ, The, 2020, 369, m1107.	3.0	7
39	Comparing Onset of Biosimilar Versus Generic Competition in the United States. Clinical Pharmacology and Therapeutics, 2020, 108, 1308-1314.	2.3	7
40	Sponsorship and Funding for Gene Therapy Trials in the United States. JAMA - Journal of the American Medical Association, 2020, 323, 890.	3.8	10
41	Grounding Valueâ€Based Drug Pricing in Population Health. Clinical Pharmacology and Therapeutics, 2020, 107, 1290-1292.	2.3	4
42	Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States. Arthritis and Rheumatology, 2020, 72, 1036-1038.	2.9	19
43	Insulin access and affordability in the USA: anticipating the first interchangeable insulin product. Lancet Diabetes and Endocrinology,the, 2020, 8, 360-362.	5.5	4
44	Preferences for and Experiences With Pill Appearance Changes: National Surveys of Patients and Pharmacists. American Journal of Managed Care, 2020, 26, 340-347.	0.8	2
45	Generic Competition for Drugs Treating Rare Diseases. Journal of Law, Medicine and Ethics, 2020, 48, 789-795.	0.4	1
46	Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administrationâ€™s Adverse Event Reporting System. Drug Safety, 2019, 42, 85-93.	1.4	5
47	Why Are Biosimilars Not Living up to Their Promise in the US?. AMA Journal of Ethics, 2019, 21, E668-678.	0.4	44
48	Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions. Journal of General Internal Medicine, 2019, 34, 2339-2341.	1.3	27
49	Orphan Drug Designation and Exclusivity for â€œSame Drugsâ€. Journal of Law, Medicine and Ethics, 2019, 47, 347-349.	0.4	1
50	Reforming the Orphan Drug Act for the 21st Century. New England Journal of Medicine, 2019, 381, 106-108.	13.9	31
51	Competition and price among brand-name drugs in the same class: A systematic review of the evidence. PLoS Medicine, 2019, 16, e1002872.	3.9	42
52	The Impact Of Price Regulation On The Availability Of New Drugs In Germany. Health Affairs, 2019, 38, 1182-1187.	2.5	19
53	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. Clinical Pharmacology and Therapeutics, 2019, 105, 1513-1521.	2.3	10
54	Tepid Steps on Drug Pricing. JAMA Internal Medicine, 2019, 179, 439.	2.6	5

#	Article	IF	Citations
55	New Drug Formulations and Their Respective Generic Entry Dates. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 218-224.	0.5	4
56	Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Medicine, 2019, 16, e1002763.	3.9	55
57	Mitigating Health Risks of Prescription Drugs. JAMA - Journal of the American Medical Association, 2019, 321, 651.	3.8	9
58	Variation in Prescription Drug Prices by Retail Pharmacy Type. Annals of Internal Medicine, 2019, 171, 605.	2.0	30
59	The <scp>US</scp> Biosimilar Market: Stunted Growth and Possible Reforms. Clinical Pharmacology and Therapeutics, 2019, 105, 92-100.	2.3	41
60	A Survey of Patientsâ€™ Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. Journal of General Internal Medicine, 2019, 34, 420-428.	1.3	8
61	Removing ERISAâ€™s Impediment to State Health Reform. New England Journal of Medicine, 2018, 378, 5-7.	13.9	15
62	Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. BMJ: British Medical Journal, 2018, 361, k1180.	2.4	27
63	Benefits, Limitations, and Value of Abuse-Deterrent Opioids. JAMA Internal Medicine, 2018, 178, 131.	2.6	9
64	Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. Clinical Pharmacology and Therapeutics, 2018, 103, 1093-1099.	2.3	13
65	The Supreme Court Ruling in Sandoz v Amgen. JAMA Internal Medicine, 2018, 178, 5.	2.6	4
66	The FDA Amendments Act of 2007 â€" Assessing Its Effects a Decade Later. New England Journal of Medicine, 2018, 379, 1097-1099.	13.9	14
67	An Incomplete Prescription. JAMA - Journal of the American Medical Association, 2018, 319, 2373.	3.8	7
68	Evaluating The Impact Of The Orphan Drug Actâ€™s Seven-Year Market Exclusivity Period. Health Affairs, 2018, 37, 732-737.	2.5	40
69	Promoting Patient Interests in Implementing the Federal Right to Try Act. JAMA - Journal of the American Medical Association, 2018, 320, 869.	3.8	22
70	Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. Health Affairs, 2017, 36, 362-370.	2.5	7
71	Strategies That Delay Market Entry of Generic Drugs. JAMA Internal Medicine, 2017, 177, 1665.	2.6	33
72	Recalibrating Privacy Protections to Promote Patient Engagement. New England Journal of Medicine, 2017, 377, 1509-1511.	13.9	5

#	Article	IF	Citations
73	Value-Based Pricing and State Reform of Prescription Drug Costs. JAMA - Journal of the American Medical Association, 2017, 318, 609.	3.8	28
74	Active Surveillance of Follow-on Biologics: A Prescription for Uptake. Drug Safety, 2017, 40, 105-108.	1.4	9
75	The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. PLoS ONE, 2017, 12, e0175313.	1.1	3
76	Navigating the Dermatological Drug Cost Curve. JAMA - Journal of the American Medical Association, 2016, 315, 2724.	3.8	1
77	Factors Influencing Prescription Drug Costs in the United Statesâ€"Reply. JAMA - Journal of the American Medical Association, 2016, 316, 2431.	3.8	1
78	Efficacy of the Priority Review Voucher Program. JAMA - Journal of the American Medical Association, 2016, 315, 1660.	3.8	1
79	The High Cost of Prescription Drugs in the United States. JAMA - Journal of the American Medical Association, 2016, 316, 858.	3.8	445
80	State Initiatives to Control Medication Costs â€" Can Transparency Legislation Help?. New England Journal of Medicine, 2016, 374, 2301-2304.	13.9	27
81	Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels. Drug Safety, 2016, 39, 709-714.	1.4	7
82	The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?. PLoS Medicine, 2016, 13, e1001955.	3.9	7
83	Regulatory Solutions to the Problem of High Generic Drug Costs. Open Forum Infectious Diseases, 2015, 2, ofv179.	0.4	4
84	Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States. PLoS Medicine, 2015, 12, e1001802.	3.9	13
85	Experience With the Priority Review Voucher Program for Drug Development. JAMA - Journal of the American Medical Association, 2015, 314, 1687.	3.8	30
86	Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs. New England Journal of Medicine, 2015, 372, 279-286.	13.9	125
87	Progress and Hurdles for Follow-on Biologics. New England Journal of Medicine, 2015, 372, 2380-2382.	13.9	43
88	Expanded Access to Investigational Drugs. New England Journal of Medicine, 2015, 372, 1473-1474.	13.9	3
89	Forbidden and Permitted Statements about Medications â€" Loosening the Rules. New England Journal of Medicine, 2015, 373, 967-973.	13.9	12
90	Ensuring Patient Privacy in Data Sharing for Postapproval Research. New England Journal of Medicine, 2014, 371, 1644-1649.	13.9	19

#	Article	IF	Citations
91	Using a Drug-Safety Tool to Prevent Competition. New England Journal of Medicine, 2014, 370, 1476-1478.	13.9	21
92	Expressing findings from metaâ€analyses of continuous outcomes in terms of risks. Statistics in Medicine, 2011, 30, 2967-2985.	0.8	55
93	Healthâ€related lifestyle in adults and children with primary immune thrombocytopenia (ITP). British Journal of Haematology, 2010, 151, 189-191.	1.2	22
94	Autologous ¹¹¹Inâ€labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry. British Journal of Haematology, 2010, 151, 477-487.	1.2	70
95	Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica, 2010, 95, 1167-1175.	1.7	197
96	Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood, 2009, 113, 1231-1240.	0.6	273
97	Health-Related Lifestyle among Adult & Pediatric Patients with Idiopathic Thrombocytopenic Purpura in the United Kingdom.. Blood, 2008, 112, 3435-3435.	0.6	1